Collaboration with ReNeuron to identify brain repair protein

01-Mar-2002
Press Release 27th February 2002 Proteome Sciences plc ("Proteome Sciences"), the AIM listed proteomics and modification of gene expression company, announces that it has entered into a collaborative research agreement with ReNeuron Holdings plc ("ReNeuron") to identify proteins expressed in brain repair in response to stroke as possible therapeutic entities or drug targets relevant for the treatment of stroke and other neurodegenerative diseases at our facilities at King's College, London. Proteome Sciences has already successfully applied its proteomics research platform to search for a reliable diagnostic marker for stroke. Using high sensitivity protein separation, Proteome Sciences has identified markers in blood for the diagnosis of stroke and which can also differentiate between stroke and heart attack. The research is currently focused on the differentiation between ischaemic and haemorragic stroke. Discussions are actively in progress with strategic licensing partners for commercialisation. The collaboration with ReNeuron will extend Proteome Sciences' programme in stroke to address further drug targets and potential therapeutic entities. The companies will jointly own intellectual property arising from the collaboration and share any resulting revenues from its commercialisation.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances